Literature DB >> 20379202

Parkinson disease: calcium channel blockers and Parkinson disease.

Ronald F Pfeiffer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20379202     DOI： 10.1038/nrneurol.2010.31

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  L-type calcium channel blockers and Parkinson disease in Denmark.

Authors:  Beate Ritz; Shannon L Rhodes; Lei Qian; Eva Schernhammer; Jørgen H Olsen; Søren Friis
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

2.  Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration.

Authors:  Haeman Jang; David Boltz; Katharine Sturm-Ramirez; Kennie R Shepherd; Yun Jiao; Robert Webster; Richard J Smeyne
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

3.  Is Parkinson's disease a prion disorder?

Authors:  C Warren Olanow; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-28       Impact factor: 11.205

4.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Authors:  C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

Review 5.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

6.  Occupation and risk of parkinsonism: a multicenter case-control study.

Authors:  Caroline M Tanner; G Webster Ross; Sarah A Jewell; Robert A Hauser; Joseph Jankovic; Stewart A Factor; Susan Bressman; Amanda Deligtisch; Connie Marras; Kelly E Lyons; Grace S Bhudhikanok; Diana F Roucoux; Cheryl Meng; Robert D Abbott; J William Langston
Journal:  Arch Neurol       Date:  2009-09

7.  Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain.

Authors:  Michael DeCuypere; Yan Lu; Duane D Miller; Mark S LeDoux
Journal:  J Neurochem       Date:  2008-12       Impact factor: 5.372

Review 8.  Clinical genetics of Parkinson's disease and related disorders.

Authors:  Christian Wider; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

9.  Robust pacemaking in substantia nigra dopaminergic neurons.

Authors:  Jaime N Guzman; Javier Sánchez-Padilla; C Savio Chan; D James Surmeier
Journal:  J Neurosci       Date:  2009-09-02       Impact factor: 6.167
  9 in total
  4 in total

1.  L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease.

Authors:  Thimmappa S Anekonda; Joseph F Quinn; Christopher Harris; Kate Frahler; Teri L Wadsworth; Randall L Woltjer
Journal:  Neurobiol Dis       Date:  2010-09-09       Impact factor: 5.996

Review 2.  Targeting microglia L-type voltage-dependent calcium channels for the treatment of central nervous system disorders.

Authors:  Sarah C Hopp
Journal:  J Neurosci Res       Date:  2020-01-29       Impact factor: 4.433

Review 3.  The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders.

Authors:  Yajin Liao; Yuan Dong; Jinbo Cheng
Journal:  Int J Mol Sci       Date:  2017-02-10       Impact factor: 5.923

4.  Blockade of microglial Cav1.2 Ca2+ channel exacerbates the symptoms in a Parkinson's disease model.

Authors:  Xinshuang Wang; Hironao Saegusa; Soontaraporn Huntula; Tsutomu Tanabe
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.